Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine

Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.

Read More »

FDA staff raises safety issues over Trevena opioid injection

Trevena Inc.’s opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. FDA said, sending the drugmaker’s shares down 66 percent.

Read More »

Minnesota sues opioid maker Insys over improper drug marketing

Minnesota became the latest state to sue Insys Therapeutics Inc., accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

Read More »

France fines J&J 25 million euros over painkiller patch

France’s competition authority fined U.S. healthcare group Johnson & Johnson 25 million euros ($29.6 million) after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.

Read More »

Billionaire founder of Insys to plead not guilty to opioid bribe scheme

The billionaire founder of Insys Therapeutics Inc. appeared in federal court in Boston to plead not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug.

Read More »

Billionaire Insys founder charged in U.S. opioid bribe case

The billionaire founder of Insys Therapeutics Inc. was arrested on U.S. charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

Read More »

Trump declares opioid epidemic a public health emergency; crisis could spread to Europe, experts say

As U.S. President Donald Trump declared the opioid crisis a public health emergency, Europe should heed the threat from opioids responsible for America’s deadliest drug epidemic in decades as both regions have seen rises in prescription rates of such medicines, which can be a gateway to dangerous derivatives according to experts.

Read More »

Trump’s drug czar nominee withdraws from consideration

President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Read More »

Scandal-Ridden Insys Replaced 90 Percent of Its Original Sales Force in Makeover

Arizona-based Insys has been plagued by kickback accusations regarding marketing of its fentanyl-based cancer pain medication Subsys, a sublingual spray. Multiple states – including New Jersey, Massachusetts and Arizona – have accused the company of fraud in order to boost sales. The company said it has replaced the bulk of its management team along with 90 percent of its original sales staff and commercial operatives.

Read More »

Arizona accuses drugmaker Insys of fraudulent opioid marketing

Arizona sued Insys Therapeutics Inc., accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom